Loading quotes...
Forecast
The analysts' average price target is €54.23 (+88.36%). The median is €51.80 (+79.92%).
| Buy |
Â
4 |
| Hold |
Â
18 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Calumet misses Q1 2026 earnings forecasts despite progress in renewable fuels
Calumet reported Q1 2026 earnings per share of -$3.64, missing analysts’ expectation of -$0.31, while revenue of $1.03 billion slightly exceeded estimates. A production outage in Shreveport due to organic chloride contamination cost about 750,000 barrels and roughly $30 million, which pushed adjusted EBITDA down to $50.1 million. Montana Renewables showed strong operational improvements (adjusted EBITDA +209%) and the MaxSAF-150 expansion began operations, while the new SET-2 RVO has significantly increased demand for biofuels and improved margins. Management expects that the resumption of production and a better market environment will lead to improved results in 2026, but continues to see challenges with the debt structure. » More on de.investing.com
Calumet announces quarterly results for 31 March 2026, analysts see significantly smaller loss
Calumet expects to release results for the quarter ended 31 March 2026 on 8 May 2026. Five analysts on average expect earnings per share of -$0.333 versus -$1.870 in the year‑ago quarter. Six analysts forecast revenue of around $1.01 billion (+1.93% year‑on‑year). For the current fiscal year the consensus estimate is $0.077 per share and revenue of about $4.41 billion. » More on finanzen.net
Calumet: supervisory board member Jennifer Straumins will not stand for re-election in 2026
Jennifer Straumins will not stand for re-election to Calumet’s supervisory board at the annual general meeting in 2026 and will leave the board at the end of her term. Straumins has been a member of the supervisory board since July 2024; she was previously a member of the board of Calumet GP, LLC and worked for the company for 13 years. She currently serves on the strategy and growth committee and the risk committee; the supervisory board now intends to review the composition and competencies of the body. » More on de.investing.com
Calumet cuts debt by $220 million, Q4 profitability remains weak
Calumet reported adjusted EBITDA of $293.3 million for 2025 and highlighted a reduction in restricted liabilities of more than $220 million. Despite cost cuts and higher production, the company missed Q4 estimates by a wide margin; diluted EPS was -$0.43 versus -$0.22 expected. The Specialty Products segment showed strong margins, while Montana Renewables was weighed down by low industry margins and transaction costs. Management emphasizes debt reduction, cash-flow improvement and the MaxSAF150 project (completion Q2 2026) as key levers to restore profitability. » More on de.investing.com
S&P raises outlook for Calumet to positive after refinancing
S&P Global Ratings has raised the outlook for Calumet from "stable" to "positive" and affirmed the rating at CCC+ after the company refinanced short-term liabilities by issuing unsecured bonds and extended the ABL maturity. S&P expects improvements in credit metrics over the next 12 months, with EBITDA margins projected to rise by about 200 basis points to roughly 8% in 2025 and to approach the 10% mark in 2026/27. Calumet’s subsidiary Montana Renewables plans to increase SAF capacity in Q2 2026 to 120–150 million gallons, and contracts already signed cover much of the expansion. Risks remain from commodity price and regulatory exposure and possible RIN-related obligations that could strain liquidity and metrics. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 1.49B | 61.74% |
| Gross profit | 479.56M | 50.60% |
| Net profit | 226.36M | 15.24% |
| EBITDA | 293.72M | 0.09% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.59B |
Number of shares | 88.09M |
52-week high/low | €54.41 - €16.22 |
| Dividends | No |
Beta | 0.78 |
P/E ratio | -14.37 |
PEG ratio | 0.04 |
P/B ratio | -3.27 |
P/S ratio | 0.55 |
Company profile
Calumet Specialty Products Partners, L.P. manufactures, formulates, and markets slate of specialty branded products to various consumer-facing and industrial markets in North America and internationally. Its Specialty Products and Solutions segment offers various solvents, waxes, customized lubricating oils, white oils, petrolatums, gels, esters, and other products. The company's Montana/Renewables segment focuses on processing renewable feedstocks into renewable hydrogen, renewable natural gas, renewable propane, renewable naphtha, renewable kerosene/aviation fuel, and renewable diesel. This segment also processes Canadian crude oil into conventional gasoline, diesel, jet fuel, and specialty grades of asphalt. Its Performance Brands segment blends, packages, and markets high performance products through Royal Purple, Bel-Ray, and TruFuel brands. Calumet GP, LLC serves as the general partner for Calumet Specialty Products Partners, L.P. The company was founded in 1916 and is headquartered in Indianapolis, Indiana.
| Name | Calumet Spec. Prods Part. ADR |
| CEO | Louis Todd Borgmann |
| Headquarters | Indianapolis,
in USA |
| Website | |
| Sector | Energy |
| Industry | Oil, Gas & Consumable Fuels |
| IPO | 01/26/2006 |
| Employees | 1,540 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | CLMT |